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Interaction of RANTES with its membrane ligands or receptors transduces multiple intracellular signals. Whether RANTES uses
proteoglycans (PGs) belonging to the syndecan family to attach to primary cells expressing RANTES G-protein-coupled receptors (GPCRs)
was investigated. We demonstrate that RANTES specifically binds to high and low affinity binding sites on human monocyte-derived
macrophages (MDM). We show by co-immunoprecipitation experiments that RANTES is associated on these cells with syndecan-1 and
syndecan-4, but neither with syndecan-2 nor with betaglycan, in addition to CD44 and its GPCRs, CCR5 and CCR1. Glycosaminidases pre-
treatment of the monocyte derived-macrophages strongly decreases the binding of RANTES to syndecan-1 and syndecan-4 and also to
CCR5, and abolishes RANTES binding to CD44. This suggests that glycosaminoglycans (GAGs) are involved in RANTES binding to the
PGs and that such bindings facilitate the subsequent interaction of RANTES with CCR5, on the MDM, characterized by low membrane
expression of CCR5. The role of these interactions in the pathophysiology of RANTES deserves further study.
D 2003 Elsevier B.V. All rights reserved.Keywords: RANTES; CCR5; Syndecan; HIV; Macrophage
1. Introduction HIV-1 primary receptor [8], but chemokine receptors haveMacrophages are thought to be one of the first type of
cells in the body to be infected during the early stage of HIV
transmission [1–5]. Moreover, macrophages together with
naive and memory T cells [4,6,7] represent a major HIV
reservoir in HIV infected individuals. Therefore, macro-
phages are key players in HIV-1 pathogenesis. CD4 is the0005-2736/$ - see front matter D 2003 Elsevier B.V. All rights reserved.
doi:10.1016/j.bbamem.2003.09.006
Abbreviations:MDM, monocyte-derived macrophages; PBL, peripheral
blood lymphocytes; PGs, proteoglycans; SD, syndecan; MIP, macrophage
inflammatory protein; MCP-1, monocyte chemoattractant protein-1;
RANTES, regulated on activation normal T cell expressed and secreted;
GAGs, glycosaminoglycans; SDF, stromal-cell derived factor; GPCRs, G-
protein-coupled receptors; BSA, bovine serum albumin; PBS, phosphate-
buffered saline; DTT, dithiothreitol; TBS, Tris-buffered saline supple-
mented; FCS, fetal calf serum; IL-8, interleukin-8; FGF-2, fibroblast growth
factor-2; hbEGF, heparin-binding epidermal growth factor
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E-mail address: liliane.gattegno@jvr.ap-hop-paris.fr (L. Gattegno).been identified as HIV coreceptors, especially CCR5 for R5
HIV strains and CXCR4 for X4 HIV strains [9–13]. We, in
accordance with others, have previously reported that in-
fection of human monocyte-derived macrophages (MDM)
and peripheral blood lymphocytes (PBL) by HIV-1 R5
strains, but not PBL by X4 strain, is inhibited by h-chemo-
kines such as RANTES or macrophage inflammatory pro-
tein (MIP)-1a [14,15], two physiological CCR5 ligands [9].
However, opposite effects of RANTES on HIV-1 infection
of macrophages have also been described [16–18]. Chemo-
kines mediate their biological activity through activation of
G protein coupled receptors (GPCRs) [19], but most chemo-
kines, including RANTES, are also able to bind to glyco-
saminoglycans (GAGs) [20–23]. Virtually, all GAGs exist
in covalent linkage to a protein core as proteoglycans (PGs).
RANTES exhibits selectivity in GAGs binding with the
highest affinity (nanomolar range) for heparin [24,25]. It has
been suggested that cell surface heparan sulfate (HS)
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receptors on specific target cells. It has also been shown that
soluble polyanions inhibit HIV infection [26–28]. More-
over, a recent study has suggested that a single family of
HSPGs, the syndecans, efficiently mediates HIV-1 attach-
ment and represent an abundant class of HIV attachment
receptors on human primary macrophages [29]. Cells sur-
face HSPGs are anchored in the cell membrane either via a
transmembrane domain (the syndecans) or by glycosyl-
phosphoinositol linkage (glypicans) [29]. In this study, we
have evaluated whether RANTES binds to syndecans
expressed on the plasma membrane of MDM.2. Materials and methods
2.1. Cells and cell culture
Peripheral bloodmononuclear cells fromcytapheresis from
healthy HIV-seronegative donors (Etablissement Francais
du Sang, Paris, France) were cultured for 5 days as previ-
ously described [14,23]. Non-adherent cells were removed.
Adherent cells were cultured as described [14,23] for at least
48 h. No contamination by T cells was observed [14,23].
K562 cells were cultured in RPMI 1640 (Invitrogen Corpo-
ration) supplemented with 10% fetal calf serum (FCS).
2.2. FACScan analysis of the cells
Aliquots of 5 105 scraped MDM were incubated for 30
min at 4 jC in 100-Al phosphate-buffered saline (PBS),
supplemented with 0.05% bovine serum albumin (BSA,
Sigma-Aldrich, Saint Quentin Fallavier, France) and with
1–2.5 Ag of anti-CD4 mAb (murine IgG1; clone Q4120;
Sigma-Aldrich), anti-CD14 mAb (murine IgG2b; Becton
Dickinson, Pont de Claix, France), anti-CCR5 mAb 2D7 or
anti-CXCR4 mAb 12G5 (mouse IgG2a; both from Phar-
mingen, Pont de Claix, France), anti-CCR1 mAb (mouse
IgG2b; clone 55504.111; R&D systems, Abigdon, UK),
anti-CD44 mAb (mouse IgG2a; clone F10-44-2; Serotec,
Oxford, UK) or the isotypes (Pharmingen). After washing,
cells were incubated for 30 min at 4 jC with FITC-labeled
goat anti-mouse Ig antibodies (1/20; Pharmingen), fixed in
1% paraformaldehyde (PFA) (Sigma-Aldrich) in PBS
(PBS–PFA) and analyzed on a FACScan (Becton Dick-
inson). Alternatively, adherent MDM were cultured in 24-
well flat-bottom plates (at about 5 105 cells per well ) in 1-
ml culture medium. After three washes with PBS, MDM
were incubated for 30 min at 4 jC in 300 Al of PBS–BSA
supplemented either with anti-syndecan-1 mAb DL-101 (10
Ag/ml; mouse IgG-1; clone DL-101, specific for an epitope
corresponding to the ectodomain of human syndecan-1,
Santa Cruz Biotechnology, California, USA), anti-synde-
can-4 mAb (10 Ag/ml; mouse IgG2a; clone 5G9, specific for
an epitope corresponding to the ectodomain of human
syndecan-4; Santa Cruz Biotechnology), anti-betaglycanAbs (10 Ag/ml; goat IgG; R&D systems) or their isotypes
(Pharmingen). In parallel, aliquots of these adherent MDM
(5 105 cells per well) were permeabilized in the presence
of 300-Al RPMI supplemented with 2% FCS and 0.3%
saponin (Sigma-Aldrich), and then incubated in this medium
for 30 min at + 4 jC with anti-syndecan-2 goat Ab (10 Ag/
ml; goat IgG, specific for an epitope corresponding to the C-
terminal domain of human syndecan-2; Santa Cruz Biotech-
nology) or its isotype. After washing, MDM were incubated
for 30 min at 4 jC in 300-Al PBS–BSA supplemented with
FITC-labeled goat anti-mouse or mouse anti-goat Ig anti-
bodies (1/20; Pharmingen), fixed in 1% paraformaldehyde
(PFA) (Sigma-Aldrich) in PBS (PBS–PFA), scrapped and
analyzed by flow cytometry.
2.3. Immunofluorescence staining and microscope analysis
of the cells
Adherent MDM, cultured on glass coverslips (at about
5 105 MDM per well), were incubated for 1 h at room
temperature in 500-Al PBS supplemented with anti-synde-
can-1 mAb DL-101 (10 Ag/ml), anti-syndecan-4 mAb 5G9
(10 Ag/ml), anti-betaglycan Ab (10 Ag/ml) or their iso-
types (10 Ag/ml). Cells were then incubated for 30 min at
room temperature, in the darkness, with a Cy-3 conjugated
donkey anti-mouse antibody (1:400; Jackson Immunore-
search, Laboratories, Inc., Baltimore, Pennsylvania, USA),
or Alexa fluor 488-labeled donkey anti-goat antibody
(Molecular Probes, Eugene, OR), fixed in PBS–PFA
and mounted in fluorescent mounting medium (Dako,
Glostrop, Denmark). In parallel, MDM were fixed with
methanol, air-dried, rehydratated with PBS and incubated
for 1 h at room temperature with anti-syndecan-2 goat Ab
(10 Ag/ml) or its isotype. Bound antibodies were revealed
with Alexa Fluor 488 labeled-donkey anti-goat secondary
antibody and observed using an Olympus fluorescence
microscope.
2.4. RANTES binding to MDM
125I-RANTES (81 TBq/mmol) was from Perkin Elmer
Life Sciences (Boston, MA, USA). For displacement bind-
ing assays, aliquots of adherent MDM (all at 5 105), were
cultured in 24-well plates (Falcon, Strasbourg, France).
After 48-h incubation in serum-free medium and three
washings with ice-cold binding buffer (PBS/0.1% BSA),
cells were incubated for 2 h at 4 jC in 0.3-ml binding buffer
containing 125I-RANTES (7.5 pM; Perkin Elmer) in the
presence or absence of unlabeled RANTES (up to 50 nM).
Incubation was terminated by removing the medium and
washing the cells. After cell lysis in 5% NaOH, bound
radioactivity was measured using a g-counter (LKB 1261
Multigamma). Data were analyzed by fitting to a logistic
curve or according to Scatchard. Results are meansF S.E.
of three independent assays, each performed in triplicate.
Alternatively, 125I-RANTES was incubated for 1 h at 37 jC
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Sigma-Aldrich) and the mixture was added to the cells.
2.5. RANTES binding to ligands or receptors
To collect RANTES ligands, scraped MDM (2 107)
were incubated in parallel for 2 h at + 4 jC with or without
RANTES (at 2.5 Ag in 500 Al of PBS). Alternatively, MDM
were preincubated for 2 h at 37 jC with heparitinase I (0.1
U/ml), heparitinase III (0.5 U/ml) and chondroitinase ABC
(0.2 U/ml) (all from Sigma) mixture. In other experiments,
MDM (2 107) were subsequently incubated in 500 Al of
PBS with RANTES (2 Ag), and after washing with anti-
RANTES mAb in 500 Al of PBS (2 Ag; mouse IgG1; clone
21445.1; R&D systems), for 2 h at + 4 jC. MDM were then
lysed at 4 jC in 500-Al buffer (150 mM NaCl, 20 mM Tris/
HCl, pH 8.2, supplemented with 1% Brij 97 and 10 mM
PMSF, 5 mM iodoacetamide, 25 mM phenanthrolin, 20 Ag/
ml aprotinin, all from Sigma-Aldrich). Lysates were cleared
by centrifugation at 1000 g for 30 min at 4 jC. Immuno-
complexes were collected in the presence of 10 mM
dithiothreitol (DTT) (Sigma-Aldrich), by incubation for 18Fig. 1. Immunofluorescence analysis of MDM. (A) MDM membrane expression
syndecan-4 (SD-4), betaglycan and CD44 by FACScan analysis. MDM were staine
mAb, anti-CD4 mAb Q4120, anti-CCR5 mAb 2D7, anti-CXCR4 mAb 12G5, anti
anti-betaglycan Ab or anti-CD44 mAb (thick lines). Reactivity was compared to a
are representative of three to eight individual experiments. (B) Immunofluore
betaglycan from MDM. Adherent MDM were immunostained, as described in M
syndecan-2 Ab (b), anti-syndecan-4 mAb 5G9 (c), goat anti-betaglycan Ab (d), or w
are representative of three individual experiments. Bar: 5 Am.h at 4 jC with 100 Al of protein G-Sepharose beads
(Pharmacia, Paris, France), precoated [30–32] or not with
anti-RANTES mAb or its isotype (each at 2.5 Ag). Weak
reducing conditions during the collection of the immuno-
complexes were used to eliminate cross-reactivity with
nonspecific proteins [33]. In parallel, the same experiments
were also performed with K562 cells.
Alternatively, the MDM were incubated with RANTES,
as just described, and lysed in the presence of Brij 97.
Aliquots of MDM lysates were then incubated with Protein
G-Sepharose beads coupled either with anti-syndecan-1
mAb DL-101, anti-syndecan-4 mAb 5G9, anti-syndecan-2
or anti-betaglycan Abs (each at 2 Ag). As negative control,
the MDM were incubated in RANTES-free buffer. Immu-
nocomplexes were then collected as just described.
To release bound ligands, beads were boiled for 10 min
with 120 Al of 2 SDS-PAGE sample buffer and centri-
fuged (400 g; 5 min; 15 jC). Lysates or eluted proteins
were submitted to SDS-PAGE (12% polyacrylamide) under
non-reducing conditions and transferred onto Immobilon
strips which were then saturated for 18 h at 37 jC with PBS
or Tris-buffered saline (TBS) supplemented with 5% BSAof CD14, CD4, CCR5, CXCR4, syndecan-1 (SD-1), syndecan-2 (SD-2),
d for FACS analysis, as described in Materials and methods, with anti-CD14
-syndecan-1 mAb DL-101, anti-syndecan-2 Ab, anti-syndecan-4 mAb 5G9,
n isotype-matched control monoclonal or polyclonal Ab (dotted lines). Data
scence microscopic analysis of syndecan-1, syndecan-2, syndecan-4 and
aterials and methods, with anti-syndecan-1 mAb, DL-101 (a), goat anti-
ith their isotypes, mouse IgG1 (e), mouse IgG2a (g) or goat IgG (f, h). Data
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supplemented with 0.5% BSA and 0.2% Tween 20 (v/v)
(Sigma-Aldrich). Strips were incubated for 1 h at room
temperature with anti-CCR5 2D7 or 3A9 (Pharmingen),
anti-syndecan-1 DL-101, anti-syndecan-2, anti-syndecan-4
5G9, anti-betaglycan, anti-CD44, anti-HS 10E4 (mouse
IgM; Seikagaku) or 3G10 (mouse IgG2b; Seikagaku),
anti-CXCR4 12G5 or G19 antibodies (G19 is a goat
polyclonal antibody from Santa Cruz Biotechnology, raised
against a peptide GYQKKLRSMTDKYRLHLSV, mimick-
ing according to Brelot et al. [34] the first extracellular
domain of CXCR4), or anti-RANTES mAb or polyclonal
Abs (R&D systems) or their isotypes (all at 1/1000–1/
5000). After three washes, strips were incubated with
HRP-labeled anti-mouse or anti-goat IgG (at 1/5000-1/
20000). After washing, strips were revealed by enhanced
chemilumiscence reagent (Amersham Pharmacia Biotech,
UK, or Supersignal West Dura Extended, Pierce). In paral-
lel, in some experiments, lysates were submitted to the
glycosaminidases mixture and then treated as just described.Fig. 2. Binding of RANTES to MDM. Binding (A) and Scatchard (B) plots
were obtained by incubating unlabeled RANTES, at the indicated
concentrations, and 125I-RANTES, at 7.5 pM, with MDM (A, B) for 2 h
at 4 jC. Results are the meansF S.E. (bars) of three separate experiments
performed in triplicate.3. Results and discussion
3.1. Immunofluorescence labeling of MDM
MDM expressed CD14, and low levels of CD4, CCR5,
CXCR4 and CCR1, as assessed by indirect immunofluores-
cence assay and FACS analysis (Fig. 1A and data not
shown). They also expressed PGs belonging to the syndecan
family, syndecan-1, syndecan-2, syndecan-4 besides other
PGs such as betaglycan and CD44 (Fig. 1A and B).
Syndecan-1, syndecan-2, syndecan-4 and betaglycan deco-
rated their plasma membrane, as revealed by microscopic
analysis (Fig. 1B).
3.2. Specific binding of RANTES to MDM
We have previously reported that RANTES binding to
MDM is inhibited by soluble heparin or chondroitin sulfate
(respectively 42% and 30% inhibition), by anti CCR5 mAb
2D7 (47%) and by heparitinase, chondroitinase or neur-
aminidase treatment of these cells (22%, 25% and 48%)
[23]. Therefore, this binding involves CCR5, and negatively
charged glycans or GAGs. In the present study, we observe
that 125I-RANTES (7.5 pM) binds in a dose-dependent and
saturable manner to MDM; this binding is significantly
inhibited by increasing concentrations of unlabeled
RANTES (Fig. 2A). Minimum 125I-RANTES binding (B/
T) to MDM, determined in the presence of 10.4 nM
unlabeled RANTES, was 13F 0.9%. Scatchard analysis of
the displacement curve (Fig. 2B), from three independent
assays of specific 125I-RANTES (7.5 pM) binding to MDM
obtained from three different blood donors, in the presence
of increasing concentrations of unlabeled RANTES (up to
10.4 nM), has revealed two classes of specific binding sites:one with 3600F 1560 binding sites per cell and a 0.260F
0.1 nM Kd and the other with 90 300F 26,000 binding sites
per cell and a 11.2F 3 nM Kd (Fig. 2B). Moreover,
125I-
RANTES binding to MDM was inhibited by 330 Ag/ml
heparin-albumin (by 43F 12% inhibition: n = 4; P < 0.05),
while albumin or dextran had no effect. Therefore,
RANTES specifically binds to high and low affinity binding
sites of MDM, and heparin presented on a protein carrier
inhibits this binding. In these experiments, because
RANTES aggregates at high micromolar concentrations,
low nanomolar concentrations of unlabeled RANTES were
used for the displacement binding assays. In these condi-
tions, it cannot be excluded that higher concentrations on
non-aggregated cold ligand may be needed to further
displace the binding of 125I-RANTES.
3.3. Binding of PGs to the complexes formed between
RANTES and GPCRs on MDM
To determine whether RANTES binds to PGs expressed
on the plasma membrane of MDM, different procedures
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RANTES: after incubation with RANTES and subsequently
with anti-RANTES antibodies, the MDM were lysed and
the immunocomplexes were collected on protein-G beads;
alternatively, the MDM were lysed just after their incubation
with RANTES and the RANTES interacting proteins were
collected on anti-RANTES coated beads. Similar data were
obtained in both experiments. Our previous studies [31,32]
have demonstrated, in accordance with others [35], that the
presence of the detergent BRIJ-97 in the cell solubilization
buffer did not modify the molecular interactions which
occur during the formation of multimolecular complexes
between a ligand and its targets, expressed on the plasma
membranes of living cells. Therefore, in the present study
the cells were lysed in the presence of this detergent.Fig. 3. Binding of syndecan-1 and syndecan-4 to the complexes formed by RANT
(lanes 2, 4, 6, 7, 9, and 11) or not (lanes 1, 3, 5, 8, 10, and 12–23) with heparitinase
not (lanes 20–23) with RANTES and then with anti-RANTES antibodies. Cells w
on SDS-12% PAGE gels, electroblotted onto Immobilon strips and revealed using a
22), anti-syndecan-4 5G9 (lanes 5, 6, and 23), anti-CD44 (lanes 8 and 9), anti-h
CXCR4 12G5 (13) mAbs, anti-syndecan-2 (lane 14), or anti-betaglycan (lane 15
shown represent one of three individual experiments, using the MDM from diffeWestern blot analysis of immunoprecipitates revealed
46–48-kDa proteins, immunoreactive with anti-CCR5
2D7 or 3A9 mAbs and anti-CCR1 mAb, but neither with
anti-CXCR4 mAb 12G5 nor with anti-CXCR4 Ab G19
(Fig. 3, lanes 1, 12 and 13, and data not shown). Further
analysis of these immunoprecipitates revealed mainly 40–
60-kDa proteins and proteins migrating as smears of appar-
ent molecular masses >250 kDa, all immunoreactive with
anti-syndecan-4 5G9, and 50–52-kDa proteins immunore-
active with anti-syndecan-1 mAb DL-101. Moreover, pro-
teins of 110 kDa, characterized by their immunoreactivity
with anti-CD44 mAb, were also detected. In addition, 40–
60-kDa proteins, 110-kDa proteins and proteins migrating
as smears of >250 kDa were also immunoreactive with anti-
HS 10E4 mAbs (Fig. 3, lanes 3, 5, 8, and 10). As it has beenES and GPCRs at the plasma membrane of MDM. MDM were pretreated
s I, III and chondroitinase ABC, and sequentially incubated (lanes 1–19) or
ere lysed. Immunocomplexes were collected on protein-G beads, separated
nti-CCR5 2D7 (lanes 1, 2, and 20), anti-syndecan-1 DL-101 (lanes 3, 4, and
eparan sulfate 10E4 (lanes 10 and 11), anti-CCR1 (lanes 12 and 21), anti-
), Abs or their isotypes, IgG2a, IgG1, IgM or IgG2b (lanes 16–19). Data
rent blood donors.
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that occurs in native heparan sulfate chains and is destroyed
by N-desulfatation of the GAG [36], these data suggest that
the PGs bound to RANTES on MDM have HS chains.
No immunoreactivity with anti-syndecan-2, anti-betagly-
can Abs nor with the isotypes was detected. No immuno-
reactivity was observed with all tested antibodies when the
MDM were incubated, as negative controls, in RANTES-
free buffer (Fig. 3, lanes 14–23).
In the same conditions, we did not detect any RANTES
ligands from the K562 cells (data not shown). As it has been
previously reported that K562 cells express betaglycan and
syndecan-3 [29], these data further rule out RANTES
binding to betaglycan.
Alternatively, we found that RANTES can be co-immu-
noprecipitated with syndecan-1 or syndecan-4 but neither
with syndecan-2 nor with betaglycan (data not shown). This
further argues for the occurrence of some selectivity in
RANTES binding to PGs expressed on MDM.
Taken together, these data indicate that beside its specific
GPCRs, CCR1 and CCR5, RANTES binds PGs belonging
to the syndecan family, syndecan-4, syndecan-1 and also
other PGs such as CD44 expressed on MDM. Therefore,
syndecan-1, syndecan-4 and CD44 molecules, but neither
syndecan-2 nor betaglycan, are associated to the complex
formed between RANTES and GPCRs on MDM.
In parallel, Western blot analysis of MDM lysates,
prepared in the presence of BRIJ 97, revealed the presence
of proteins migrating as smears: one characterized by
apparent molecular masses ranging from about 40 to 80
kDa, and immunoreactive with anti-syndecan-1 mAb DL-
101, and the other by masses ranging from 34 to 60 kDa,
immunoreactive with anti-syndecan-4 mAb 5G9 (Fig. 4,
lanes 1 and 4). No immunoreactivity with the respective
isotypes was detected (Fig. 4, lanes 3 and 6). GAGs removal
from the PGs, by glycosaminidase treatment of theseFig. 4. Immunoblot analysis of syndecan-1 and syndecan-4 from MDM
lysates MDM lysates, treated (lanes 2 and 5) or not (lanes 1, 3, 4 and 6)
with heparitinases I, III and chondroitinase ABC, were submitted to SDS-
PAGE, electroblotted and revealed with anti-syndecan-1 mAb DL 101
(lanes 1 and 2), anti-syndecan-4 mAb 5G9 (lanes 4 and 5) or their isotypes,
mouse IgG1 (lane 3) or IgG2a (lane 6). Data shown are representative of
three individual experiments, using the MDM from different blood donors.lysates, induced a shift of the apparent molecular masses
of these PGs, to 45 kDa for the PGs immunoreactive with
the anti-syndecan-1 mAb DL-101, and to 31–33 kDa for
those immunoreactive with anti-syndecan-4 mAb 5G9 (Fig.
4, lane 2 versus 1 and 5 versus 4).
Taken together, these data indicate that some of the
syndecan-4 molecules bound by RANTES were further
oligomerized in the presence of the chemokine, and suggest
that the syndecan-1 and syndecan-4 molecules bound by the
chemokine are glycanated.
3.4. GAGs dependence of RANTES binding to syndecan-1
and -4
If the MDM were pre-treated with heparitinases I and III,
and chondroitinase ABC mixture, a decrease in the immu-
noreactivity of the RANTES-bound material with anti-
syndecan-1 DL-101, anti-syndecan-4 5G9 and anti-CCR5
2D7 mAbs was observed (Fig. 3, lane 4 versus 3, lane 6
versus 5 and lane 2 versus 1). This suggests that GAGs
removal from the cells by glycosaminidases treatment has
decreased the binding of RANTES to syndecan-1, synde-
can-4 and CCR5. Moreover, we also observed in these
conditions a shift of the respective apparent molecular
masses of the PGs bound by RANTES, from 50–52 kDa
to 45 kDa for RANTES bound syndecan-1, and from more
than 250 and 40–60 kDa, respectively, to 33 kDa for
RANTES bound syndecan-4 (Fig. 3, lane 4 versus 3 and
lane 6 versus 5).
The 45-kDa proteins were immunoreactive not only with
the anti-syndecan-1 mAb DL-101 but also with the anti-stub
3G10 mAb, while the 33-kDa proteins were immunoreac-
tive not only with anti-syndecan-4 mAb 5G9 but also with
3G10 mAb (Fig. 3, lanes 4, 6 and 7). Moreover, in these
conditions, no RANTES bound CD44 was detected, which
demonstrates that RANTES binding to CD44 expressed on
MDM is GAGs-dependent (Fig. 3, lane 9).
These data indicate that GAGs-dependent binding of
RANTES to syndecan-1, syndecan-4 and CD44 may facil-
itate RANTES subsequent interaction with CCR5 on MDM
characterized by low membrane expression of CCR5. How-
ever, these data do not rule out that subsequent interactions
of RANTES with the respective core proteins of syndecan-1
or syndecan-4 may also occur.4. Conclusion
Syndecans are HSPGs involved in specific binding of
growth factors and growth factors receptors. For instance, it
has been previously demonstrated that syndecan-2,
expressed on human MDM, selectively binds the macro-
phage-derived growth factors, fibroblast growth factor-2
(FGF-2), vascular endothelial growth factor and heparin-
binding epidermal growth factor (hbEGF), but not chemo-
kines, such as MIP-1a, MIP-1h, monocyte chemoattractant
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MDM express high levels of syndecan-1 and syndecan-4
and low levels of syndecan-3 [29]. In addition, MDM also
express betaglycan, CD44 but not glypican-1 [29,38,39].
We have investigated here whether besides its GPCRs,
RANTES uses HSPGs belonging to the syndecan family,
to bind to human primary macrophages. We have confirmed
by specific immunostaining the MDM membrane expres-
sion of syndecan-1, syndecan-2, syndecan-4, betaglycan and
CD44. We have also observed low membrane MDM ex-
pression of CXR4, CCR5 and CCR1 [14,15,17,40]. We
have previously reported that RANTES binding to MDM is
inhibited by anti-CCR5 mAb 2D7 and by heparitinase
pretreatment of the cells [23], suggesting the role of both
HSPGs and GPCRs. To further investigate the role of these
molecules in RANTES binding, we have analyzed here the
binding characteristics of RANTES to human primary
macrophages. Few studies have reported displacement bind-
ing assays to cells, of iodine-labeled RANTES by unlabeled
RANTES [41]. Here, we show that RANTES specifically
binds to MDM, in a dose-dependent and saturable manner
with two classes of binding sites, high affinity ones char-
acterized by a 0.26 nM Kd, and low affinity ones charac-
terized by a 11.2 nM Kd. These Kd values are in agreement
with those previously reported respectively for the binding
of h-chemokines to CCR5 [42] or of RANTES to heparin
[24]. Exogenous heparin-albumin also inhibits this binding.
Because RANTES aggregates at high micromolar concen-
trations, low nanomolar concentrations of unlabeled
RANTES were used for the displacement binding assays.
Therefore, it cannot be excluded that higher concentrations
of cold non-aggregated RANTES would be needed to
further displace the binding of 125I-RANTES.
The biological activity of chemokines has been shown to
be influenced by their association with GAGs [37,41]. For
example, the presence of GAGs attached to the cell surface
has been reported to increase the binding affinity of
RANTES to CCR1 and others GPCRs [41]. Enzymatic
removal of GAGs from lymphocytes was reported to abro-
gate the ability of RANTES to elicit an intracellular Ca2 +
signal [43]. However, in another work, no effect of cell
surface GAGs was found on chemokine binding [24]. It was
also demonstrated that removal of GAGs from the surface of
a PM1 T cell line or from MDM reduces the antiviral effect
of RANTES [15,28]. Moreover, enzymatic removal of
GAGs from the surface of CCR5 expressing CHO cells
by different glycosidases did not result in a reduction of the
ability of RANTES to bind CCR5 or to induce a functional
response [24]. Therefore, studies on the role of GAGs on
RANTES binding and function are often conflicting.
Our data show that RANTES, added to the plasma
membrane of intact MDM, induces the formation of com-
plexes which comprise glycanated syndecans, syndecan-1
and syndecan-4, and also another PG, CD44, besides the
specific RANTES GPCRs, CCR5 and CCR1, but neither
syndecan-2 nor betaglycan. RANTES binding to CD44expressed on HeLa cells has been recently demonstrated
[38]. In the present study, pretreatment of the MDM with
glycosaminidases decreases the binding of RANTES to
syndecan-1, syndecan-4, and CCR5. Such pretreatment also
abolishes the binding of RANTES to CD44. This indicates
that GAGs-dependent binding of RANTES to syndecan-1,
syndecan-4 and CD44 facilitates the subsequent interaction
of this chemokine with CCR5 on MDM, which are charac-
terized here by a low membrane expression of CCR5.
In the present study, we have not detected any RANTES
GPCRs, syndecan-1, syndecan-2 or syndecan-4 molecules,
neither on the plasma membrane of the human K562
leukemia cells nor in their lysates. Moreover, no RANTES
ligands were detected on these cells. As it has been
previously reported that K562 cells express betaglycan
and syndecan-3 [29], these data further rule out RANTES
binding to betaglycan. However, whether RANTES also
binds to PGs belonging to the glypican family has to be
investigated. The reason why such interactions of RANTES
with syndecan-1, syndecan-4 and CD44 but neither with
syndecan-2 nor betaglycan occurs has now to be investigat-
ed. Whether this may be related with differences in GAG
composition (HS versus CS) of the PGs and/or degree of
GAG side chains or higher sulfatation deserves further
study.
In conclusion, the present data show that besides CD44,
PGs belonging to the syndecan family, syndecan-1 and
syndecan-4, but neither syndecan-2 nor betaglycan, serve
as ligands for RANTES on human primary macrophages.
The GAGs dependence of RANTES binding to syndecan-1
and syndecan-4 does not rule out that additional subsequent
protein–protein interactions may take place. Whether these
molecules belonging to the syndecan family also serve as
signaling receptors involved in specific functions remains to
be investigated. For instance, syndecan-4 possesses a phos-
phoinositol 4,5-biphosphate binding site in its cytoplasmic
tail that allows it to bind and activate protein kinase Ca
[44,45]. The role of the respective associations of RANTES
with syndecan-1 and syndecan-4 in signal transduction, in
the pathophysiology of chemokines or GPCRs, and in HIV
infection deserves further study.Acknowledgements
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